|
|
Blood, 1 November 2008, Vol. 112, No. 9, pp. 3537-3538.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Comment on Steele et al, page 3827
Suppressing the tumor suppressor in CLL?
Chris Pepper
CARDIFF UNIVERSITY
In this issue of Blood, Steele and colleagues present a series of elegant experiments that illuminate a p53 transcription-independent mechanism of apoptosis induction in primary CLL cells.
As is the case in most human cancers, loss of function or deletion of the p53 tumor suppressor gene signals bad news in chronic lymphocytic leukemia (CLL).1 The reasons for this are complex, but clearly the majority of current treatments induce apoptosis via a p53-dependent pathway. Although p53 has been traditionally considered a transcription factor, there is growing evidence that it also causes extranuclear effects that can induce powerful cellular responses independent of de novo gene transcription.2 In this issue of Blood, Steele et al present compelling evidence that CLL cells preferentially employ a transcription-independent mechanism of apoptosis. They demonstrate that treatment-induced p53 is predominantly found in the mitochondrial fraction of cell extracts and is associated with the antiapoptotic protein Bcl-2. Furthermore, they show that the p53 transcription-blocking agent pifithrin  can enhance chlorambucil- and fludarabine-mediated apoptosis. This result is somewhat counterintuitive, but the authors conclude that the net effect of p53-induced transcription is the blockade of a transcription-independent apoptotic pathway. Therefore, selective inhibition of p53-mediated transcription by pifithrin results in increased cell killing.
View larger version (34K):
[in this window]
[in a new window]
|
The combination of chemotherapy with p53 inhibitors enhanced CLL-cell apoptosis. In contrast, normal T cells were resistant to this combination of agents.
|
|
These results are intriguing but defy simple interpretation. For instance, it is not clear whether the effects of pifithrin are truly the consequence of blocked transcription. It may be tempting to simplistically consider that pifithrin blocks the transcription of the ubiquitin ligase MDM2, thereby stabilizing p53 and preventing its degradation.3 Indeed, this paper presents evidence for pifithrin –mediated inhibition of MDM2. However, p53 is capable of inducing/repressing hundreds of genes, so a painstaking dissection of global gene expression profiles induced by pifithrin in CLL would seem necessary. This approach may yield a list of "likely suspects" that can be specifically inhibited using the gene silencing methodologies that are now available for the manipulation of CLL cells. Furthermore, a number of alternative explanations beyond transcriptional repression are possible. Pifithrin may simply prevent p53 nuclear import, thereby sequestering it in the cytoplasm where it is free to interact with Bcl-2 family proteins. In this regard, the coimmunoprecipitation of Bcl-2 and p53 from CLL cell extracts presented here is intriguing. Can cytoplasmic p53 displace Bax from a Bcl-2/Bax complex, thereby triggering the Bax conformational change observed in this study? Alternatively, it has recently been suggested that p53 can even act directly on the mitochondrial permeability transition pore complex in order to induce apoptosis.4 All of these possibilities can be tested experimentally, and so it seems inevitable that further revelations will be forthcoming in the near future.
This work has raised a number of very interesting biologic questions, but the key clinical question is, can we exploit p53 transcription blockers to augment current chemotherapeutics? The answer at the moment is a guarded "maybe." Promisingly, pifithrin has been shown to be relatively nontoxic to normal tissue in mouse models,5 and this present study shows little evidence of pifithrin –mediated apoptosis in normal human T cells. However, additional studies involving the coadministration of standard chemo-therapies are clearly warranted. Another concern is that this strategy may only be effective when the CLL cells have a functional p53 pathway. p53 dysfunction is much more prevalent in advanced-stage and drug-resistant patients, so the clinical utility of this approach may be limited in this context.
Despite the unresolved questions and the probable clinical caveats, this paper provides fascinating new insights into the biological machinery of CLL cells. It seems likely that we will be able to exploit this new knowledge in the future to develop more effective treatments for this common but as yet incurable disease.
Footnotes
Conflict-of-interest disclosure: The author declares no competing financial interests. 
REFERENCES
- Grever MR, Lucas DM, Johnson AJ, et al. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007;20:545–556.[Medline]
[Order article via Infotrieve]
- Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577–590.[CrossRef][Medline]
[Order article via Infotrieve]
- Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299.[CrossRef][Medline]
[Order article via Infotrieve]
- Wolff S, Erster S, Palacios G, et al. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008;18:733–744.[CrossRef][Medline]
[Order article via Infotrieve]
- Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med. 2008;14:125–133.[CrossRef][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism
- Andrew J. Steele, Archibald G. Prentice, A. Victor Hoffbrand, Birunthini C. Yogashangary, Stephen M. Hart, Elisabeth P. Nacheva, Julie D. Howard-Reeves, Veronique M. Duke, Panagiotis D. Kottaridis, Kate Cwynarski, Lyubomir T. Vassilev, and R. Gitendra Wickremasinghe
Blood 2008 112: 3827-3834.
[Abstract]
[Full Text]
[PDF]
|
|
